Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab.

Abstract

In the search for new pharmacologic therapies for central giant cell granuloma (CGCG), proteins that are essential to osteoclastogenesis are intriguing potential targets. In the present case report, we describe a 25-year-old patient with an aggressive CGCG of the maxilla, who was successfully treated with the antiresorptive agent denosumab, after other pharmacologic treatment had failed to achieve regression or stabilization of the tumor. Denosumab could be a promising alternative to potentially mutilating surgery for CGCG. However, more research is needed before definite conclusions can be drawn about the potential role of this agent in the treatment of CGCG.

• Authors: Willem H Schreuder, Annet W Coumou, Peter A H W Kessler, Jan de Lange
• Journal: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons (J Oral Maxillofac Surg) Vol. 72 Issue 7 Pg. 1301-9 (Jul 2014) ISSN: 1531-5053 [Electronic] United States
• PMID: 24835517 (Publication Type: Journal Article)
• Copyright: Copyright © 2014 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• RANK Ligand
• Denosumab

Topics

• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Denosumab
• Female
• Granuloma, Giant Cell (diagnostic imaging, drug therapy, pathology)
• Humans
• Mouth Neoplasms (diagnostic imaging, drug therapy, pathology)
• RANK Ligand (antagonists & inhibitors)
• Tomography, X-Ray Computed